Research
Energy balance
Tirzepatide and semaglutide are not cost-effective at current net prices, requiring significant discounts to meet cost-effectiveness thresholds.
Healthcare providers should consider the cost-effectiveness of these medications when making treatment decisions.
StrongRefutesmedium confidence
This economic evaluation found that although tirzepatide and semaglutide offered substantial long-term health benefits, they were not cost-effective at current net prices.
Why this rating
Based on a lifetime cost-effectiveness analysis using a validated model.
Source
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
Jennifer H. Hwang et al. · JAMA Health Forum · 2025
DOI 10.1001/jamahealthforum.2024.5586
other · n=4823Cited 50×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →